The progression of HCC in the era of DAA therapy is critical in determining the onset or
recurrence of cancer after HCV eradication. DAAs have shown satisfactory efficacy in the treatment of
HCV-sustained viral response (SVR). However, data on HCC risk following DAA-SVR remains
contradictory. 1 The purpose of this study is to look at HCC onset in people who have the moderate
underlying liver disease by detecting levels of IDO enzyme that show a massive increase in HCC
patients compared to recently diagnosed patients with HCV infection and cirrhosis-related HCV
patients.2 These findings raise the possibility that in considering IDO, more than an enzyme, as a
marker predicting the development of HCC after HCV eradication. It’s also possible that DAA therapy
may be the cause of rising IDO levels, which requires further investigation.so we conducted this work
aiming to compare the level of IDO enzyme with the progression of HCC despite curing with DAA
therapy and studying the effect of therapy on patients by analyzing the severity and predicting suitable
biomarkers for detecting HCC occurrence in cured patients from HCV infection by DAA that progress
HCC.
|
